INTRODUCTION
============

Pancreatic cancer (PC) is the fourth leading cause of cancer mortality in the United States, with 38,460 deaths annually.^[@B1]^ Five-year survival for all stages combined is only 6%. Gemcitabine had beenthe backbone treatment for years in advanced disease,^[@B2]^ until the introduction of FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin)^[@B3]^ and gemcitabine plus albumin-bound nab-paclitaxel^[@B4]^ regimens, both reported after initiation of our trial. Despite numerous attempts, most gemcitabine combinations with molecularly targeted therapies have failed to demonstrate a significant improvement in overall survival (OS),^[@B5]--[@B8]^ with the exception of gemcitabine plus erlotinib, which has demonstrated a statistically significant but clinically modest benefit.^[@B9]^

Vismodegib (Erivedge; Genentech, South San Francisco, CA), a synthetic small-molecule inhibitor of smoothened (SMO) in the hedgehog (Hh) pathway,^[@B10],[@B11]^ has demonstrated clinical benefit in basal cell carcinoma and medulloblastoma---both harboring recurrent Hh pathway mutations in *SMO* or protein patched homolog 1 (*PTCH1*).^[@B12],[@B13]^ Vismodegib is US Food and Drug Administration approved for the treatment of patients with advanced basal cell carcinoma. Trials applying various SMO inhibitors to other tumors harboring genomic activation of the Hh signaling pathway are under way, some within novel clinical trial designs.^[@B14]^ However, no single-agent activity was observed in early phase I studies within molecularly unselected patients with advanced and pretreated PC.^[@B15],[@B16]^

Nevertheless, the Hh pathway has been reported to be critical for tumor progression in preclinical PC models^[@B17],[@B18]^ and has been considered a potential therapeutic target.^[@B19]--[@B21]^ Sonic Hh (SHH) is overexpressed in approximately 70% of PCs and has been shown to be an early and late mediator of PC tumorigenesis.^[@B22]--[@B24]^ Tumor-derived SHH has influenced and promoted tumor growth in preclinical PC systems by activating Hh signaling in stroma.^[@B25]--[@B28]^ This paracrine Hh signaling may establish and maintain the desmoplastic stroma observed in PC, creating a barrier for proper drug penetration.^[@B29]^ Hh pathway inhibition with IPI-269609, an SMO inhibitior,^[@B30]--[@B32]^ reportedly led to increased tumor perfusion, enhanced tumor delivery of gemcitabine when coadministered, and improvement in survival in a genetically engineered murine PC model,^[@B29]^ forming the rationale for human clinical trials in PC.

Given this background, we hypothesized that inhibition of the Hh pathway would be synergistic with gemcitabine and would lead to improved progression-free survival (PFS) compared with gemcitabine alone for metastatic PC.^[@B33]^ This article reports the final results of a phase Ib (n = 7) and multicenter randomized phase II trial (n = 106) comparing gemcitabine plus vismodegib (GV) with gemcitabine plus placebo (GP) in patients with advanced PC; there were no significant differences in overall response rate (ORR), PFS, or OS between these two groups. To further investigate the putative biologic mechanisms of SMO inhibition, we used two autochthonous PC models (Kras^G12D^; p16/p19^fl/fl^; Pdx1-Cre \[KPP\] and Kras^G12D^; p53^R270H/wt^; Pdx1-Cre \[KR\]) to recapitulate the phase II clinical trial. In contrast to recent reports with IPI-926 (saridegib),^[@B29],[@B34]--[@B36]^ our preclinical and clinical results with vismodegib are concordant and demonstrate no statistically significant differences with respect to tumor growth, drug delivery, or treatment efficacy.

PATIENTS AND METHODS
====================

The Data Supplement provides detailed information on methods.

RESULTS
=======

Clinical Trial
--------------

### Patient characteristics.

Seven patients were enrolled onto the phase Ib open-label GV portion, and no safety issues were identified. For the randomized phase II part of the trial, 111 patients were enrolled at 13 sites between February 2010 and June 2012, stratified by Karnofsky performance score (80 *v* 90 or 100) and disease status (newly diagnosed *v* recurrent; [Fig 1](#F1){ref-type="fig"}). Of these, four patients withdrew consent before starting treatment (two from each arm), and one patient (randomly assigned to GV) was subsequently found to have been ineligible and never started therapy. Analyses were based on the remaining 106 patients. Patient characteristics were similar between treatment arms, except for the incidence of peritoneal metastases, which were higher in the GP arm (9% *v* 23%; [Table 1](#T1){ref-type="table"}).

![CONSORT diagram of clinical trial enrollment and treatment in phase II trial. gem, gemcitabine.](zlj9991057000001){#F1}

###### 

Baseline Patient Demographic and Clinical Characteristics

![](zlj03615-5700-t01)

  Characteristic                                        No. (%)             
  ----------------------------------------------------- --------- --------- ---------
  Age, years                                                                
      Median                                            64        64        64
      Range                                             49-82     39-84     39-84
  Sex                                                                       
      Male                                              31 (58)   27 (51)   58 (55)
      Female                                            22 (42)   26 (49)   48 (45)
  Race                                                                      
      White                                             40 (77)   45 (88)   85 (83)
      African American                                  10 (19)   6 (12)    16 (16)
      Asian                                             1 (2)     0 (0)     1 (1)
      Other                                             1 (2)     0 (0)     1 (1)
      Missing                                           1         2         3
  Karnofsky performance score                                               
      100                                               19 (36)   17 (32)   36 (34)
      90                                                14 (26)   20 (38)   34 (32)
      80                                                20 (38)   16 (30)   36 (34)
  Disease status at enrollment                                              
      Newly diagnosed                                   48 (91)   48 (91)   96 (91)
      Recurrent metastatic                              5 (9)     5 (9)     10 (9)
  Primary tumor location                                                    
      Head                                              23 (43)   24 (46)   47 (45)
      Neck/uncinate                                     1 (2)     2 (4)     3 (3)
      Body                                              16 (30)   11 (21)   26 (25)
      Tail                                              13 (25)   13 (25)   26 (25)
  Site of metastasis[\*](#TF1-1){ref-type="table-fn"}                       
      Liver                                             41 (77)   44 (83)   85 (80)
      Lung                                              12 (23)   14 (26)   26 (25)
      Peritoneum                                        5 (9)     12 (23)   17 (16)
      Other                                             8 (15)    10 (19)   18 (17)
  Crossover to GV                                                 22 (42)   

Abbreviations: GP, gemcitabine plus placebo; GV, gemcitabine plus vismodegib.

Patients may have \> one primary or metastatic site.

### Safety.

Median number of cycles was four (range, one to 12 cycles) in the GV arm and three (range, zero to 14 cycles) in the GP arm. Combination therapy with GV was generally well tolerated and did not result in unexpected toxicities ([Table 2](#T2){ref-type="table"}). There were no statistically significant differences in the rate of adverse events (AEs) between the arms. Four patients in the GV arm and two in the GP arm withdrew from treatment as a result of AEs. Sixteen patients (GV, n = 10; GP, n = 6) died while receiving treatment.

###### 

Grade 3 to 5 Toxicities at Least Possibly Related to Treatment

![](zlj03615-5700-t02)

  Toxicity                         No. (%)   *P*       
  -------------------------------- --------- --------- -----
  Neutropenia                      15 (28)   12 (23)   .66
  Fatigue                          7 (13)    4 (8)     .53
  Anorexia                         5 (9)     2 (4)     .44
  Vomiting                         5 (9)     2 (4)     .44
  WBC decreased                    5 (9)     7 (13)    .76
  Platelet count decreased         6 (11)    5 (9)     1.0
  Anemia                           4 (8)     7 (13)    .53
  Nausea                           4 (8)     3 (6)     1.0
  Elevated AST                     5 (9)     3 (6)     .72
  Elevated ALT                     3 (6)     2 (4)     1.0
  Blood bilirubin increased        3 (6)     1 (2)     .62
  Hyperglycemia                    3 (6)     3 (6)     1.0
  Hypokalemia                      4 (8)     2 (4)     .68
  Alkaline phosphatase increased   2 (4)     2 (4)     1.0
  Lymphocyte count decreased       2 (4)     5 (9)     .44
  Hyponatremia                     1 (2)     5 (9)     .20

Abbreviations: GP, gemcitabine plus placebo; GV, gemcitabine plus vismodegib.

### Efficacy.

ORRs were similar in the two arms (GV: complete response \[CR\], 0 \[0%\]; partial response \[PR\], 4 \[8%\]; stable disease \[SD\], 27 \[51%\]; disease control \[ie, CR + PR + SD\], 31 \[58%\]; GP: CR, 1 \[2%\]; PR, 6 \[11%\]; SD, 20 \[38%\]; disease control, 27 \[51%\]). The difference in response rates (8% *v* 13%) was not significant (*P* = .53; Data Supplement).

The primary end point of the study was PFS. At the final analysis, events (progression or death) occurred in 48 patients (91%) receiving GV and 51 (95%) receiving GP. Median PFS was 4.0 months for GV and 2.5 months for GP (adjusted hazard ratio \[HR\], 0.83; 95% CI, 0.55 to 1.23; [Fig 2](#F2){ref-type="fig"}A; Data Supplement).

![(A) Progression-free and (B) overall survival by treatment arm. Blue, gemcitabine plus vismodegib; gold, gemcitabine plus placebo. Hazard ratio (HR) after adjusting (adj) for Karnofsky performance score and disease status (newly diagnosed *v* recurrent).](zlj9991057000002){#F2}

Median OS was 6.9 months for GV and 6.1 month for GP (adjusted HR, 0.96; 95% CI, 0.64 to 1.44; [Fig 2](#F2){ref-type="fig"}B; Data Supplement). No survival differences were noted in a preplanned secondary analysis of OS that censored patients receiving GP at first progression, before crossover to GV (*P* = .69). Note that patient crossover did not affect the primary end point (ie, PFS), because crossover happened after the event occurred. For patients receiving GP who crossed over at progression (n = 22 \[42%\]), median PFS was 1.8 months, and median OS was 2.9 months (Data Supplement). One-year survival rates in the GV and GP arms were 15% and 25%, respectively (*P* = .3). OS and PFS did not differ significantly by Karnofsky performance score (*P* = .66 and .42, respectively; Data Supplement). Mortality and disease progression rates were consistent and uniformly high across all centers.

Clinical Trial Correlative Results
----------------------------------

### SHH serum levels.

Median pretreatment plasma SHH level pooled for both treatment arms was 1.01 ng/mL (GV arm, 1.01 ng/mL; GP arm, 1.06 ng/mL). SHH levels did not change significantly with subsequent cycles (*P* = .087), nor was there a difference between treatment groups (*P* = .85) or patients with cancer (n = 89) and normal controls (n = 40; *P* = .4) ([Figs 3](#F3){ref-type="fig"}A and [3](#F3){ref-type="fig"}B). SHH serum levels did not correlate with age in either patients with cancer (*r* = 0.17; *P* = .13) or controls (*r* = 0.03; *P* = .87; [Figs 3](#F3){ref-type="fig"}C and [3](#F3){ref-type="fig"}D).

![Clinical trial translational correlatives. Serum SHH levels (A) comparing controls (n = 40) with patients with pancreatic cancer enrolled onto trial (n = 89), (B) by treatment group (gemcitabine plus vismodegib \[GV\] or gemcitabine plus placebo \[GP\]) with increasing treatment (TX) cycle, and association with age in (C) patients with cancer and (D) controls. (E) Radiologic correlatives evaluating association of baseline tumor perfusion with tumor response to therapy.](zlj9991057000003){#F3}

### Radiologic tumor perfusion.

By univariable analysis, baseline computed tomography (CT) perfusion of the primary tumor was not associated with response to therapy, expressed as percent change in tumor size (*r* = −0.09; *P* = .77; [Fig 3](#F3){ref-type="fig"}E; Data Supplement).

Murine Translational Correlatives
---------------------------------

### SMO inhibition does not reveal quantifiable changes to tumor stroma in vivo.

Previous preclinical studies have suggested that SHH is abnormally expressed in genetically engineered models of PC.^[@B29],[@B37]^ SHH expression and pathway activation were confirmed in the KPP genetically engineered mouse model of PC by transcriptional gene analysis and immunohistochemistry. SHH immunoreactivity exhibited focal staining throughout tumors, predominantly in mucinous and well-defined ductal epithelial cells (data not shown), consistent with previous reports.^[@B26]^ Comparative transcriptional analysis of normal pancreas and tumor revealed significantly elevated expression of Hh ligands *SHH* and Indian Hh (*IHH*), as well as *SMO*, glioma-associated oncogene family zinc finger 1 (*GLI1*), *GLI2*, Hh Interacting Protein (*HHIP*), and *PTCH*1 (Data Supplement).

To determine whether inhibition of SMO leads to changes in tumor stroma, we used a small molecule, HhAntag,^[@B38]^ a potent orally available preclinical surrogate of the US Food and Drug Administration--approved vismodegib (GDC-0449).^[@B10]^ Previous reports have shown that antagonism of Hh signaling resulted in increased mean microvessel density (MVD).^[@B29]^ HhAntag treatment on tumor-bearing KPP animals revealed no significant change in MVD ([Fig 4](#F4){ref-type="fig"}A; *P* = .54; Data Supplement), despite observing pathway inhibition (Data Supplement). Moreover, HhAntag treatment did not affect intratumoral extracellular matrix deposition assessed through trichrome staining ([Fig 4](#F4){ref-type="fig"}B; *P* = .29).

![Effects of hedgehog pathway antagonism (HhAntag) on vasculature, stromal content, and intratumoral gemcitabine metabolites in Kras^G12D^; p16/p19^fl/fl^; Pdx1-Cre (KPP) tumors. (A) Quantitation of immunohistochemical staining for meca-32 expression in pancreatic tumors of KPP mice treated with vehicle (circles; n = 13) or smoothened (SMO) inhibitor (squares; n = 13) for 10 days. Data presented as percentages of meca-32--positive areas over analyzed tumor areas for each tumor (Mann-Whitney *P* = .54; scale bar, 200 um). (B) Quantitative analysis of stromal content by trichromatic stain in pancreatic tumors of KPP mice treated with vehicle or SMO inhibitor for 10 days. Data presented as percentages of positive stain areas over analyzed tissue areas (Mann-Whitney *P* = .29). (C) Mass spectromic quantitation of intratumoral concentration of 2′,2′-difluorodeoxycytidine triphosphate (dFdCTP; active form of gemcitabine) from each tumor after treatment for 10 consecutive days with vehicle or SMO inhibitor and gemcitabine 50 mg/kg 30 minutes before tumor collection (Mann-Whitney *P* = 1.000). (D) Ratios of 2′,2′-difluoro 2′-deoxycytidine (dFdC) to diflurodeoxyuridine (dFdU) in pancreatic tumors from each tumor (Mann-Whitney *P* = .48). NS, not significant.](zlj9991057000004){#F4}

### SMO inhibition does not affect gemcitabine drug delivery in vivo.

The modest response rates observed in patients with PC treated with gemcitabine has, in part, been attributed to poor drug delivery associated with a prohibitive tumor microenvironment. Gemcitabine undergoes intracellular conversion, from 2′,2′-difluoro 2′-deoxycytidine (dFdC) to the active triphosphate form 2′,2′-difluorodeoxycytidine triphosphate (dFdCTP), responsible for inhibition of DNA synthesis and repair. To directly measure drug delivery, dFdCTP levels were analyzed in PC tumors of KPP mice after continuous 10-day HhAntag treatment and a single dose of gemcitabine. Liquid chromatography--tandem mass spectrometry analysis revealed that dFdCTP concentrations were similar in both vehicle- and HhAntag-treated KPP mice ([Fig 4](#F4){ref-type="fig"}C; Mann-Whitney *P* = 1.00). Intracellular gemcitabine is also converted to an inactivated form, diflurodeoxyuridine (dFdU). The ratio of the unprocessed form (dFdC) to inactive form (dFdU) estimates intratumoral gemcitabine exposure. The average ratio of dFdC to dFdU in KPP tumors of HhAntag-treated mice was not significantly different between vehicle and SMO inhibitor groups ([Fig 4](#F4){ref-type="fig"}D; *P* = .48). Together, these results indicated that HhAntag did not increase gemcitabine delivery in this genetically engineered PC mouse model.

### Pancreatic tumor progression and OS remain unaltered by Hh pathway inhibition.

Next, we investigated the therapeutic impact of HhAntag in KPP mice. Growth rates of tumors, as determined by serial ultrasound imaging, were not significantly different when comparing HhAntag and vehicle arms, indicating no single-agent effect of Hh pathway inhibition ([Figs 5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B). Although the combination of gemcitabine plus HhAntag significantly decreased tumor growth relative to control treatment (log-rank *P* = .0052), the growth rate was not different from that of gemcitabine alone, known to affect tumor growth in this model.^[@B39]^ Consistent with the lack of tumor growth effect, the HhAntag plus gemcitabine combination did not provide significant improvement in OS when compared with gemcitabine alone ([Fig 5](#F5){ref-type="fig"}C). In summary, the addition of HhAntag did not affect tumor growth or animal longevity in the KPP model.

![Smoothened (SMO) inhibitor does not affect tumor progression or overall survival in Kras ^LSL-G12D^; p16/p19 ^fl/fl^; Pdx1-Cre (KPP) mice. (A) Individual tumor growth rates plotted by from serial ultrasound images as volumes depicted longitudinally by animal within each regimen. (B) Antilogged values of slopes in each longitudinal plot are graphed, and average tumor burden fold changes per day in each study group of KPP mice are shown, with approximate 95% CIs (vehicle *v* SMO inhibitor, *P* = .86; vehicle *v* combination, *P* = .0156; gemcitabine *v* combination, *P* = .18) (C) Kaplan-Meier plots of KPP mice treated with vehicle (blue, n = 15; median, 1.9 weeks), SMO inhibitor (gold, n = 16; median, 1.2 weeks), gemcitabine (gray, n = 14; median, 3.8 weeks), and gemcitabine plus SMO inhibitor combination (red, n = 12; median, 3.4 weeks; gemcitabine *v* vehicle, *P* = .0059; combination *v* vehicle, *P* = .0179; gemcitabine *v* combination, *P* = .10 \[all *P* values from log-rank test\]). HhAntag, hedgehog pathway antagonism.](zlj9991057000005){#F5}

### Analysis of SMO inhibition in KR mice.

Although the KPP model represents the genetics of a subset of the PC population, previous findings were generated in a model composed of mutant *KRAS* and mutant *p53* expression in the pancreas.^[@B40]^ Therefore, we reproduced all in vivo studies in the KR model. HhAntag treatment on tumor-bearing KR animals revealed a significant decrease in MVD using meca-32 (Data Supplement; *P* = .0418) and trend toward decrease using CD31 (Data Supplement; *P* = .29). Trichrome staining revealed no significant changes to the stroma of HhAntag-treated tumors (Data Supplement; *P* = .83). Together these findings indicated that as in the previous KPP model, the stroma of the developed KR tumors was not significantly affected by HhAntag treatment.

Finally, we observed no significant change in concentration of the gemcitabine metabolite dFdCTP in tumors after HhAntag (Data Supplement; *P* = .25) and no significant change in the ratio of dFdC to dFdU (Data Supplement). Furthermore, neither HhAntag nor the gemcitabine plus HhAntag combination affected tumor growth rates in KR animals compared with gemcitabine alone (Data Supplement). Consistent with the tumor growth study, HhAntag did not lead to survival benefit over vehicle or gemcitabine treatment (Data Supplement). Taken together, neither of the murine PC model genotypes (KPP or KR) demonstrated any measurable differences between gemcitabine delivery to tumors, tumor growth rate, or OS with HhAntag treatment. A significant decrease in microvessel density, consistent with previous work in transplantable models using vismodegib, was observed.^[@B41]^

DISCUSSION
==========

Effective molecularly targeted treatment for advanced PC remains an unmet need. When we began this trial, extensive preclinical evidence provided rationale for the clinical evaluation of Hh pathway inhibition along with concurrent gemcitabine treatment.^[@B19],[@B22],[@B24],[@B25],[@B29],[@B32]^

The addition of vismodegib to gemcitabine in this clinical study was well tolerated, no unexpected toxicities were observed, and there were no significant toxicity differences compared with the GP arm ([Table 2](#T2){ref-type="table"}). Unfortunately, this trial failed to meet its primary objective of a statistically significant improvement in median PFS, achieving a median PFS of 4.0 and 2.5 months in the GV and GP arms, respectively (HR, 0.83; 95% CI, 0.55 to 1.23). It should be noted, however, that the study was powered (85%) to detect an HR of 0.6, and therefore, a smaller effect, if present, may not have been detectable. Similarly, there were no differences between arms in median OS (6.9 *v* 6.1 months) or disease control rate (58% *v* 51%).

Despite a recent report suggesting that serum SHH levels were decreased in patients with PC compared with age-matched controls, we did not observe this association.^[@B42]^ Moreover, we hypothesized that serum SHH might change over time, potentially differentially with or without exposure to vismodegib, but as noted, this was not observed either. Consistent with these findings, Kim et al^[@B43]^ recently reported no change in tumor SHH protein expression in matched biopsies from patients treated for 3 weeks with vismodegib.

To investigate the discrepancy between our clinical data and previous reports,^[@B24],[@B25],[@B29]^ we sought to assess baseline primary pancreatic tumor perfusion and its association with response to therapy. Perfusion CT is a clinical technique used to provide regional maps and obtain quantitative measurements of hemodynamic parameters on the basis of the linear relationship between CT enhancement and iodinated contrast material concentration.^[@B44],[@B45]^ Whole-organ perfusion of the pancreas using dynamic contrast-enhancement imaging revealed significantly lower perfusion in the tumor compared with adjacent normal pancreatic tissue.^[@B46]^ In addition, enhancement patterns of PCs on conventional dynamic multidetector row CT correlated with degree of angiogenesis, and these patterns were reportedly modified by degree of fibrosis.^[@B47]^ However, we did not observe a correlation between higher baseline tumor perfusion and improved treatment response to gemcitabine (pooled analysis, GV + GP) in this univariable analysis of a small exploratory cohort. Because there were no significant differences in clinical outcomes between the GV and GP arms, evaluation of serial changes in perfusion over time was not performed.

Much of the preclinical work supporting Hh inhibition for PC was performed with IPI-296 (saridegib).^[@B29],[@B31]^ It is noteworthy that a randomized phase II trial of saridegib in PC, conducted simultaneously with our trial, was halted at interim analysis in January 2012 because of worse median PFS and median OS compared with the placebo arm.^[@B36]^ A recent report attempting to discern the preclinical^[@B29]^ to clinical^[@B36]^ discrepancy suggested that prolonged exposure to IPI-296 before frank tumor development (PanIN stage) ultimately led to tumors with undifferentiated histology, increased vascularity, and heightened proliferation.^[@B34]^ Importantly, clinical correlates to confirm the original^[@B29]^ or newly reported^[@B34]^ preclinical findings, including increased vascularity, improved drug delivery, and worsened disease resulting from IPI-296 treatment, are still lacking or unreported. Subsequently, a similar preclinical study evaluating vismodegib treatment, also at the tumor precursor stage (PanIN), reported accelerated tumor progression.^[@B35]^ Here, further support for the critical role of stroma early in pancreatic tumor formation was provided with elegant studies, where *SHH* was genetically deleted coincident with tumor suppressor loss and oncogene activation. In the absence of epithelial-derived SHH secretion, the resulting pancreatic tumors were phenotypically distinct, devoid of desmoplastic stroma, more vascularized, and more proliferative than controls.^[@B34],[@B35]^ The early treatment design of these experiments is consistent with a large body of work describing the preventive nature of stroma in early tumor formation,^[@B48]--[@B50]^ but it does little to reconcile the preclinical and clinical discrepancy with Hh inhibition in established pancreatic tumors. The discordance between the preclinical^[@B29]^ (benefit) and clinical^[@B36]^ (detriment) results with IPI-926 in established tumor scenarios may be a result of overinterpretation of the preclinical gemcitabine model data,^[@B29]^ because small yet statistically significant effects do not ensure a biologically meaningful effect in patients. This lack of predictive correlation contrasts the strong predictive value of preclinical work in models harboring mutationally driven Hh pathway signaling.^[@B51]^ Patient-derived xenograft models may also promote better understanding in the future.

Patients with PC frequently present with advanced disease, so to model the clinical treatment scenario, we treated two independent, genetically engineered PC models when defined, measurable tumors were readily detectable. Not only did SHH pathway inhibition not improve survival, no measurable changes in gemcitabine delivery or tumor growth rate were observed in either murine model. An increase in vascular density was not observed with vismodegib treatment, in contrast to IPI-926.^[@B29]^ In our study, HhAntag treatment showed a significant or trending decrease in microvessel density, depending on the marker used, which is consistent with previous work in preclinical tumor models where vismodegib treatment reduced tumor growth and mean vessel density.^[@B41]^

It is also possible that the preclinical efficacy differences may be attributed to unique molecular properties of the agents, given that IPI-926 is a cyclopamine derivative, whereas GDC-0449 (vismodegib) is a synthetic inhibitor of SMO. For example, although both molecules occupy a similar pocket within the transmembrane domain of SMO, they may mechanistically diverge, because cyclopamine treatment leads to accumulation of SMO in the primary cilium, whereas vismodegib prevents it.^[@B52],[@B53]^ Moreover, cyclopamine has been shown to have off-target effects that may lead to enhanced toxicity and/or potentially cause the stromal effects observed. Notably, a clinical trial with IPI-926 in PC was stopped because of worse survival outcome in the investigational arm.^[@B36]^ In our study, we did not observe increased toxicity or a detriment in survival with GV. Nevertheless, neither molecule demonstrated statistically significant improvement when combined with gemcitabine in PC.

In conclusion, we found no benefit in adding vismodegib to gemcitabine in this randomized phase II trial of molecularly unselected patients with metastatic PC; we corroborated these findings in two independent genetic murine PC models (KPP and KR). Given the discrepant results between the two tested SMO inhibitors, their selectivity may uniquely diverge, where off-target effects might explain altered outcomes. Importantly, our preclinical findings were ultimately concordant with the outcome of our clinical trial. Given that newer chemotherapy regimens have demonstrated benefit over gemcitabine, a number of ongoing trials are evaluating the role vismodegib in PC using these more active cytotoxic backbones.^[@B54]^
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